Cosmos Health Inc./$COSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Ticker
$COSM
Sector
Primary listing
Employees
149
Headquarters
Website
COSM Metrics
BasicAdvanced
$19m
-
-$0.63
4.46
-
Price and volume
Market cap
$19m
Beta
4.46
52-week high
$1.32
52-week low
$0.28
Average daily volume
1.1m
Financial strength
Current ratio
1.003
Quick ratio
0.608
Long term debt to equity
33.788
Total debt to equity
108.388
Interest coverage (TTM)
-6.31%
Profitability
EBITDA (TTM)
-15.18
Gross margin (TTM)
12.10%
Net profit margin (TTM)
-29.33%
Operating margin (TTM)
-25.34%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-17.26%
Return on equity (TTM)
-89.13%
Valuation
Price to revenue (TTM)
0.172
Price to book
0.82
Price to tangible book (TTM)
1.4
Price to free cash flow (TTM)
-1.302
Free cash flow yield (TTM)
-76.80%
Free cash flow per share (TTM)
-0.284
Growth
Revenue change (TTM)
19.93%
Earnings per share change (TTM)
-45.98%
3-year revenue growth (CAGR)
9.04%
10-year revenue growth (CAGR)
61.71%
3-year earnings per share growth (CAGR)
-73.29%
10-year earnings per share growth (CAGR)
-26.27%
COSM News
AllArticlesVideos
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
Accesswire·2 days ago
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Accesswire·3 days ago
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
Accesswire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cosmos Health Inc. stock?
Cosmos Health Inc. (COSM) has a market cap of $19M as of April 23, 2026.
What is the P/E ratio for Cosmos Health Inc. stock?
The price to earnings (P/E) ratio for Cosmos Health Inc. (COSM) stock is 0 as of April 23, 2026.
Does Cosmos Health Inc. stock pay dividends?
No, Cosmos Health Inc. (COSM) stock does not pay dividends to its shareholders as of April 23, 2026.
When is the next Cosmos Health Inc. dividend payment date?
Cosmos Health Inc. (COSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Cosmos Health Inc.?
Cosmos Health Inc. (COSM) has a beta rating of 4.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.